US-based biopharmaceutical firm Helix BioPharma has opened patient screening for the ninth dose level group in its ongoing Phase I/II trial of L-DOS47 in Poland (LDOS002).

The open-label Phase I/II clinical trial is designed to assess the safety, tolerability and preliminary efficacy of ascending doses of L-DOS47, initially as a monotherapy, in patients with inoperable, locally advanced, recurrent or metastatic, non-squamous, stage IIIb/IV NSCLC.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The opening of patient screening follows completion of the first treatment cycle in the three patients enrolled in the eighth dose level group, in which L-DOS47 therapy was well tolerated, as reviewed by the Trial Steering Committee.

"The company will have taken an important step in the development of L-DOS47."

Helix president and chief executive officer Robert Verhagen said: "With the continued dose escalation, now in the ninth dose level cohort for our Polish study, and the recent US Food and Drug Administration approval of the LDOS001 Phase I study, the company will have taken an important step in the development of L-DOS47."

L-DOS47 is the company’s first immunoconjugate-based drug candidate being developed based on a new DOS47 technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells.

See Also:

L-DOS47 is currently being clinically assessed as a treatment for certain patients with non-small cell lung cancer (NSCLC).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the company, patients to be enrolled in the ninth group will receive the next L-DOS47 dose level as planned in the trial protocol, which is 1.84mcg of L-DOS47 a kilogram of patient body weight.

Approved in the US, LDOS001 is an open-label Phase I dose escalation trial of L-DOS47, in combination with standard doublet therapy of pemetrexed/carboplatin in patients with Stage IV (TNM M1a and M1b) recurrent or metastatic non-squamous NSCLC.